person · Reporting owner

Giacobello Scott M.

Disclosed activity across 2 companies

Tapewire entity: 46412
SEC CIK: 0001754154

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Whitehawk Therapeutics, Inc.WHWK · Entity 6074	CHIEF FINANCIAL OFFICER	September 15, 2026	September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Whitehawk Therapeutics, Inc.

Report date September 15, 2026 · Filed September 18, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2036-09-15	Direct	118,476	Reported balance After 2026-09-15 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-09-15 · Grant · Acquired 118,476 · Balance 118,476 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	118,476	Reported balance After 2026-09-15 transaction · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · 2026-09-15 · Grant · Acquired 118,476 · Balance 118,476 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.

F3: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

GW PHARMACEUTICALS PLC

Report date May 05, 2021 · Filed May 07, 2021

Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-05-05 transaction · row 1 1 source row Row 1 · 2021-05-05 · Disposition to issuer · Disposed 165,108 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.64 · Expires 2027-05-18	Direct	Reported balance After 2021-05-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-05-05 · Disposition to issuer · Disposed 67,164 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2028-02-26	Direct	Reported balance After 2021-05-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-05-05 · Disposition to issuer · Disposed 68,460 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01	Direct	Reported balance After 2021-05-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-05-05 · Disposition to issuer · Disposed 44,184 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-05-05 · Disposition to issuer · Disposed 8,136 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-05-05 · Disposition to issuer · Disposed 10,404 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-05-05 · Disposition to issuer · Disposed 83,844 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-05-05 · Disposition to issuer · Disposed 12,576 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-05-05 · Disposition to issuer · Disposed 144,828 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-05-05 · Disposition to issuer · Disposed 86,928 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-05-05 · Disposition to issuer · Disposed 43,824 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2021-05-05 · Disposition to issuer · Disposed 70,092 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date.

Filing footnotes · ownership attribution and instrument terms

F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).

F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.

F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.

F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.

F5: These stock options were granted with automatic vesting on exercisable date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 15, 2026 Filed Sep 18, 2026 20:45 UTC Amendment	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	GrantRestricted Stock Units · Derivative	118,476	$0.00	$0.00	Disclosure SEC source: 0001754154-26-000016 · form4a-09182026_080953.xml · derivative · entry 2 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,476 Underlying: Common Stock · 118,476 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. F3 · derivative.expiration_date: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document
September 15, 2026 Filed Sep 18, 2026 20:45 UTC Amendment	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	GrantStock Option (right to buy) · Derivative	118,476	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001754154-26-000016 · form4a-09182026_080953.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,476 Underlying: Common Stock · 118,476 shares Expires 2036-09-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document
September 15, 2026 Filed Sep 15, 2026 23:07 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	GrantRestricted Stock Units · Derivative	118,476	$0.00	$0.00	Disclosure SEC source: 0001754154-26-000014 · form4-09152026_110910.xml · derivative · entry 2 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,476 Underlying: Common Stock · 118,476 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document
September 15, 2026 Filed Sep 15, 2026 23:07 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	GrantStock Option (right to buy) · Derivative	118,476	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001754154-26-000014 · form4-09152026_110910.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,476 Underlying: Common Stock · 118,476 shares Expires 2036-09-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document
May 14, 2026 Filed May 18, 2026 20:04 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	GrantCommon Stock	38,265	$3.92	$149,998.80	Disclosure SEC source: 0001754154-26-000012 · form4-05182026_080534.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,489 Read SEC document
April 16, 2026 Filed Apr 17, 2026 20:53 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	SaleCommon Stock	141,600	$4.13	$584,808.00	Disclosure SEC source: 0001754154-26-000010 · form4-04172026_080413.xml · nonDerivative · entry 2 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,224 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
April 15, 2026 Filed Apr 17, 2026 20:53 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	SaleCommon Stock	77,000	$3.86	$297,220.00	Disclosure SEC source: 0001754154-26-000010 · form4-04172026_080413.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,824 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes an aggregate of 11,822 shares of Common Stock acquired between November 14, 2022 and November 15, 2025 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document
April 01, 2026 Filed Apr 3, 2026 22:18 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	GrantStock Option (right to buy) · Derivative	300,677	$0.00 Strike: $3.54	$0.00	Disclosure SEC source: 0001754154-26-000005 · form4-04032026_100439.xml · derivative · entry 3 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,677 Underlying: Common Stock · 300,677 shares Expires 2036-04-01 F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026. Read SEC document
April 01, 2026 Filed Apr 3, 2026 22:18 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	Exercise / conversionRestricted Stock Units · Derivative	473,902	$0.00	$0.00	Disclosure SEC source: 0001754154-26-000005 · form4-04032026_100439.xml · derivative · entry 2 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 473,902 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. F2 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. Read SEC document
April 01, 2026 Filed Apr 3, 2026 22:18 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	Exercise / conversionCommon Stock	473,902	Not disclosed	Not disclosed	Disclosure SEC source: 0001754154-26-000005 · form4-04032026_100439.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. Read SEC document
March 02, 2026 Filed Mar 10, 2026 23:36 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	SaleCommon Stock	2,594	$3.31	$8,585.10	Disclosure SEC source: 0001754154-26-000002 · form4-03102026_110300.xml · nonDerivative · entry 2 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,100 F2 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
March 01, 2026 Filed Mar 10, 2026 23:36 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	Exercise / conversionRestricted Stock Units · Derivative	6,750	$0.00	$0.00	Disclosure SEC source: 0001754154-26-000002 · form4-03102026_110300.xml · derivative · entry 3 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 6,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. Read SEC document
March 01, 2026 Filed Mar 10, 2026 23:36 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	Exercise / conversionCommon Stock	6,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001754154-26-000002 · form4-03102026_110300.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. Read SEC document
April 01, 2025 Filed Apr 3, 2025 23:23 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	GrantRestricted Stock Units · Derivative	473,902	$0.00	$0.00	Disclosure SEC source: 0001415889-25-010079 · form4-04032025_110445.xml · derivative · entry 2 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,902 Underlying: Common Stock · 473,902 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. Read SEC document
April 01, 2025 Filed Apr 3, 2025 23:23 UTC	Whitehawk Therapeutics, Inc. WHWK · Entity 6074	GrantStock Option (right to buy) · Derivative	473,902	$0.00 Strike: $1.70	$0.00	Disclosure SEC source: 0001415889-25-010079 · form4-04032025_110445.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,902 Underlying: Common Stock · 473,902 shares Expires 2035-04-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. Read SEC document
March 03, 2025 Filed Mar 4, 2025 01:38 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	SaleCommon Stock	2,806	$2.35	$6,594.10	Disclosure SEC source: 0001415889-25-006318 · form4-03042025_010336.xml · nonDerivative · entry 2 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,944 F2 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
March 01, 2025 Filed Mar 4, 2025 01:38 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	Exercise / conversionRestricted Stock Units · Derivative	6,750	$0.00	$0.00	Disclosure SEC source: 0001415889-25-006318 · form4-03042025_010336.xml · derivative · entry 3 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,250 Underlying: Common Stock · 6,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. Read SEC document
March 01, 2025 Filed Mar 4, 2025 01:38 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	Exercise / conversionCommon Stock	6,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-006318 · form4-03042025_010336.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. Read SEC document
March 01, 2024 Filed Mar 5, 2024 00:12 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	GrantRestricted Stock Units · Derivative	27,000	$0.00	$0.00	Disclosure SEC source: 0001415889-24-006411 · form4-03052024_120310.xml · derivative · entry 3 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. F4 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. Read SEC document
March 01, 2024 Filed Mar 5, 2024 00:12 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	GrantStock Option (right to buy) · Derivative	55,000	$0.00 Strike: $1.92	$0.00	Disclosure SEC source: 0001415889-24-006411 · form4-03052024_120310.xml · derivative · entry 2 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2034-03-01 F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 1, 2024. Read SEC document
March 01, 2024 Filed Mar 5, 2024 00:12 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	GrantStock Option (right to buy) · Derivative	138,263	$0.00 Strike: $1.92	$0.00	Disclosure SEC source: 0001415889-24-006411 · form4-03052024_120310.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,263 Underlying: Common Stock · 138,263 shares Expires 2034-03-01 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall be fully vested on the Grant Date, subject to such Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the Grant Date. "Grant Date" shall mean March 1, 2024. This option comprises a portion of the Reporting Person's bonus for 2023 performance. Read SEC document
April 03, 2023 Filed Apr 4, 2023 20:07 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	GrantStock Option (right to buy) · Derivative	100,000	$0.00 Strike: $7.47	$0.00	Disclosure SEC source: 0001209191-23-022657 · doc4.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · CFO, Interim CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-04-03 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the option shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 3, 2023. Read SEC document
March 01, 2023 Filed Mar 2, 2023 21:08 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	GrantStock option (right to buy) · Derivative	90,000	$0.00 Strike: $10.93	$0.00	Disclosure SEC source: 0001209191-23-014603 · doc4.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the option shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 1, 2023. Read SEC document
September 26, 2022 Filed Sep 27, 2022 23:17 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	GrantCommon Stock	20,000	$12.50	$250,000.00	Disclosure SEC source: 0001209191-22-051388 · doc4.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document
April 01, 2022 Filed Apr 6, 2022 00:17 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	GrantStock option (right to buy) · Derivative	46,400	$0.00 Strike: $17.24	$0.00	Disclosure SEC source: 0001209191-22-023350 · doc4.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,400 Underlying: Common Stock · 46,400 shares Expires 2032-04-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the option shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2022. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	70,092	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 12 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 70,092 shares Expires not disclosed F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	43,824	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 11 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 43,824 shares Expires not disclosed F4 · price: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F4 · derivative.exercise_date: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	86,928	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 10 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 86,928 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	144,828	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 9 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 144,828 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	12,576	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 8 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,576 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	83,844	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 7 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 83,844 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	10,404	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 6 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,404 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	8,136	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 5 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,136 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	44,184	Not disclosed Strike: $14.33	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 4 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 44,184 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	68,460	Not disclosed Strike: $9.61	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 3 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 68,460 shares Expires 2028-02-26 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	67,164	Not disclosed Strike: $8.64	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · derivative · entry 2 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 67,164 shares Expires 2027-05-18 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerOrdinary Shares	165,108	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-018661 · doc4.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document
March 02, 2021 Filed Mar 4, 2021 21:07 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	43,824	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-010024 · doc4.xml · derivative · entry 2 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,824 Underlying: Ordinary Shares · 43,824 shares Expires not disclosed F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F6 · security: The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document
March 02, 2021 Filed Mar 4, 2021 21:07 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	70,092	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-010024 · doc4.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,092 Underlying: Ordinary Shares · 70,092 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F6 · security: The share numbers underlying options granted on February 22, 2021 and reported on the reporting person's form 4 filed on February 24, 2021 were amended as of March 2, 2021 and as reported in this form 4. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:25 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionShare Options · Derivative	6,288	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-009212 · doc4.xml · derivative · entry 9 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,288 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of March 1, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:25 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	3,300	$17.85	$58,905.00	Disclosure SEC source: 0000899243-21-009212 · doc4.xml · nonDerivative · entry 6 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,108 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:25 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	6,288	$0.00	$8.80	Disclosure SEC source: 0000899243-21-009212 · doc4.xml · nonDerivative · entry 5 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document
February 26, 2021 Filed Mar 2, 2021 21:25 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionShare Options · Derivative	10,404	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-009212 · doc4.xml · derivative · entry 8 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,404 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
February 26, 2021 Filed Mar 2, 2021 21:25 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionShare Options · Derivative	138,756	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-009212 · doc4.xml · derivative · entry 7 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 138,756 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
February 26, 2021 Filed Mar 2, 2021 21:25 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	5,447	$17.90	$97,501.30	Disclosure SEC source: 0000899243-21-009212 · doc4.xml · nonDerivative · entry 4 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,120 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
February 26, 2021 Filed Mar 2, 2021 21:25 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	10,404	$0.00	$14.57	Disclosure SEC source: 0000899243-21-009212 · doc4.xml · nonDerivative · entry 3 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document
February 26, 2021 Filed Mar 2, 2021 21:25 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	72,649	$17.90	$1,300,417.10	Disclosure SEC source: 0000899243-21-009212 · doc4.xml · nonDerivative · entry 2 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,163 F3 · kind: Withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
February 26, 2021 Filed Mar 2, 2021 21:25 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	138,756	$0.00	$194.26	Disclosure SEC source: 0000899243-21-009212 · doc4.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document
February 22, 2021 Filed Feb 24, 2021 18:45 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	70,128	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-008086 · doc4.xml · derivative · entry 2 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,128 Underlying: Ordinary Shares · 70,128 shares Expires not disclosed F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document
February 22, 2021 Filed Feb 24, 2021 18:45 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	43,812	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-008086 · doc4.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,812 Underlying: Ordinary Shares · 43,812 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.